⚖️Pille vs. Spritze📊Klinische DatenAktualisiert 2026

Orforglipron vs. Ozempic

Die Zukunft des Abnehmens: Pille oder Spritze? (2026)

Orforglipron ist Eli Lillys orale GLP-1-Pille — keine Injektion, keine Nüchtern-Vorgabe. Vergleichen Sie sie mit dem Goldstandard Ozempic.

Dashboard
Your complete health overview in one place
🔥
14-day streak
Logged 18 of 18 scheduled shots
Next Shot Reminder
ACTIVE MEDICATIONS
OrforglipronB12
ORFORGLIPRON
🔥 14
2
days away
Thursday · 7.5mg
Medication Supply
Orforglipron
6.2 / 10 mg · Vial
~42 days left · Mar 15
B12
4.4 / 5 ml · Vial
~88 days left · May 8
Retatrutide
1.2 / 5 mg · Vial
~6 days left · refill soon
Medication Levels
7 Days2 Weeks1 Month90 Days
CURRENT LEVEL
5.42mg
Mar 6
Today
ACTIVE MEDICATIONS
OrforglipronRetatrutide
0mg2.7mg5.4mg
18
Total Injections
💉 All time
122/78
Average BP
🩺 mmHg
8.4
Avg Mood
😊 /10
Health Chart
1mAll
218.6lb
↓ 8.4 lb · 3.7%
WeightInjectionsBPMood
2282222162102277.5mg7.5mg4mg10mg218
Feb 6Feb 14Feb 22Mar 2Today
Photos
12 photos · 2w streak
Week 1
Week 7
Today
Scheduled Reminders
Weight
Due today
Mood
Done
Blood Pressure
Tomorrow
Body Measurements
In 3 days
Dashboard
Your complete health overview in one place
🔥
14-day streak
Logged 18 of 18 scheduled shots
Next Shot Reminder
ACTIVE MEDICATIONS
OrforglipronB12
ORFORGLIPRON
🔥 14
2
days away
Thursday · 7.5mg
Medication Supply
Orforglipron
6.2 / 10 mg · Vial
~42 days left · Mar 15
B12
4.4 / 5 ml · Vial
~88 days left · May 8
Retatrutide
1.2 / 5 mg · Vial
~6 days left · refill soon
Medication Levels
7 Days2 Weeks1 Month90 Days
CURRENT LEVEL
5.42mg
Mar 6
Today
ACTIVE MEDICATIONS
OrforglipronRetatrutide
0mg2.7mg5.4mg
18
Total Injections
💉 All time
122/78
Average BP
🩺 mmHg
8.4
Avg Mood
😊 /10
Health Chart
1mAll
218.6lb
↓ 8.4 lb · 3.7%
WeightInjectionsBPMood
2282222162102277.5mg7.5mg4mg10mg218
Feb 6Feb 14Feb 22Mar 2Today
Photos
12 photos · 2w streak
Week 1
Week 7
Today
Scheduled Reminders
Weight
Due today
Mood
Done
Blood Pressure
Tomorrow
Body Measurements
In 3 days
01COMPARISON

Orforglipron vs. Ozempic: Auf einen Blick

ORFORGLIPRON
Orforglipron
  • Nicht-peptidischer oraler GLP-1-Agonist
  • Keine Nüchternheit bei Einnahme erforderlich
  • ~14,7% Gewichtsverlust nach 36 Wochen (Phase 2)
  • Tägliche Einnahme als Tablette
  • In Phase-3-Studien (Eli Lilly)
OZEMPIC
Ozempic
  • Klassischer GLP-1-Rezeptor-Agonist
  • Unterdrückt Appetit und verzögert Magenentleerung
  • ~15% Gewichtsverlust (STEP-Studien)
  • Wöchentliche Injektion
  • Langzeitdaten zur Sicherheit vorhanden
02FULL DATA

Detaillierter Vergleich

📊 Detaillierter Vergleich
Ozempic = winning arm
MerkmalOrforglipronOzempic
AnwendungTäglich oralWöchentlich subkutanBest
VorteilKeine Nadeln, flexiblerNur 1x pro Woche nötig
StatusIn Zulassung (Phase 3)Zugelassen & Etabliert
03BACKGROUND

Which Should You Choose?

Orforglipron (oral non-peptide glp-1 receptor agonist) and Semaglutide (glp-1 receptor agonist) serve different clinical roles despite both being in the Oral GLP-1 agonist space. Orforglipron small molecule oral glp-1 receptor agonist that does not require fasting for absorption — unlike oral semaglutide. Semaglutide long-acting glp-1 receptor agonist that suppresses appetite, slows gastric emptying, and enhances glucose-dependent insulin secretion.

Whichever you choose, track your protocol in Shotlee to build clean data for dose optimization and outcomes comparison.

Track Both in Shotlee
Shotlee supports tracking any medication or peptide. Compare your results across different protocols with clean dose logs and outcome data.
04DEEP DIVE

Making an Informed Choice Between Orforglipron and Ozempic

Choosing between Orforglipron and Ozempic depends on multiple individual factors including your specific health goals, tolerance profile, insurance coverage, and prescriber recommendation. While clinical trial data provides population-level efficacy and safety comparisons, your personal response may differ based on genetics, baseline health, concurrent conditions, and lifestyle factors. Use this comparison as a starting framework and discuss the specifics with your healthcare provider.

Head-to-head clinical trial data between Orforglipron and Ozempic is the gold standard for comparison, but such direct comparisons are not always available for every pair of compounds. Where head-to-head data is lacking, cross-trial comparisons provide useful but imperfect approximations — differences in patient populations, trial design, and endpoint definitions mean that numbers from separate trials are not directly interchangeable. Keep this context in mind when evaluating the comparison data presented here.

Tracking your personal response data in Shotlee is particularly valuable when switching between medications or considering a change. By documenting your outcomes on your current protocol — including efficacy metrics, side effect profile, adherence rate, and quality of life measures — you create an objective baseline for comparison if you transition to the alternative compound. This data transforms a subjective switching decision into an evidence-based protocol optimization.

05FAQ

Orforglipron vs Ozempic: Häufig gestellte Fragen

Die Markteinführung wird für 2026 erwartet, sobald die Phase-3-Studien abgeschlossen sind.

Free · Always

Orforglipron oder Ozempic in Shotlee tracken

Kostenloses Dosis-Tracking, Protokollierung von Nebenwirkungen und Ergebnisvergleich für jedes Medikationsprotokoll.

📚References & sources

Start tracking